Cannabis mixtures studied as treatment for COVID inflammation

On: February 18, 2021

Working with GB Sciences, the Las Vegas-based R&D arm of the Canadian company GBS Global Biopharma, Michigan State University (MSU) professor Norbert Kaminski is using proprietary cannabinoid-containing complex mixtures (CCCM) in an attempt to treat Cytokine Release Syndrome (CRS) and associated conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) in […]

Cannabis mixtures studied as treatment for COVID inflammation is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Previous Post: Cannabinoids can improve skin, study says

Next Post: California medical cannabis dispensary owes $4.2 million, US Tax Court rules

Comments are closed, but trackbacks and pingbacks are open.